Results 101 to 110 of about 3,770,580 (314)
Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? [PDF]
, 2008 Antibody-based therapeutics currently enjoy unprecedented success, growth in research and revenues, and recognition of their potential. It appears that the promise of the "magic bullet" has largely been realized.
Dimitrov, Dimiter S, Marks, James D
core +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background PIK3CA‐related overgrowth spectrum (PROS) includes several rare overgrowth disorders resulting from somatic gain‐of‐function mutations in PIK3CA. Despite treatment advances, including the recent approval of alpelisib for PROS in the United States, literature detailing the patient experience with PROS is limited.
Vamsi Bollu +8 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT End‐of‐life conversations with adolescents and young adults (AYAs) with cancer rarely occur without the guidance of healthcare professionals. As a part of the ‘Difficult Discussions’ study, focused on palliative care and advance care planning discussions with AYAs with cancer, we investigated the factors that healthcare professionals identify ...
Justine Lee +9 more
wiley +1 more source
Brazilian Journal of Psychiatry, 2016 Objective: To conduct a systematic literature review of animal and human studies reporting anxiolytic or antidepressive effects of ayahuasca or some of its isolated alkaloids (dimethyltryptamine, harmine, tetrahydroharmine, and harmaline).
Rafael G. dos Santos +3 more
doaj +1 more source
, 2022 Background. It is difficult to create schemes for the treatment of pathological conditions in athletes. Many medicines contain substances included in the World Anti-Doping Code Prohibited List, and for the use of a Prohibited Substance for therapeutic reasons the athlete must apply for and obtain a Therapeutic Use Exemption TUE.
Timercan, T.V., Jucov, A.V.
openaire +1 more source
Therapeutic use of radiolabelled peptides
Annals of Oncology, 2000 The inhibitory effect of somatostatin (SS) on hormone secretion led to its use in the treatment of diseases. SS itself is unsuitable for this purpose because of its very short half-life in plasma after intravenous injection and because of its diversity of actions, such as lowering insulin levels.
Krenning, Eric, Jong, Marion
openaire +3 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose Pediatric central nervous system (CNS) tumors often recur despite multimodality therapy. Although re‐irradiation (re‐RT) has historically been limited by concerns for severe late toxicities, modern techniques have renewed interest in this approach. Proton therapy provides dosimetric advantages that may enable curative re‐treatment with
Jin‐Ho Song +15 more
wiley +1 more source
Bulletin of the World Health Organization, 2002 OBJECTIVE: To assess the efficacy of chloroquine and sulfadoxine/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum infections in Somalia.
Warsame M. +6 more
doaj
Therapeutic Use Exemptions and the Doctrine of Double Effect
, 2017 Without taking a position on the overall justification of anti-doping regulations, I analyse the possible justification of Therapeutic Use Exemptions (TUEs) from such rules.
Pike, Jon
core +1 more source
Defining Roles in Pediatric Palliative Care: Perspectives From Oncology and Palliative Care Teams
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Early integration of pediatric palliative care (PPC) is associated with improved symptom management, quality of life, and healthcare utilization for children with cancer. Despite this, variation persists in how PPC is understood, operationalized, and integrated within pediatric oncology programs. In particular, ambiguity surrounding
Leeat Granek +13 more
wiley +1 more source